SWX: ROP

Explore the latest insights on SWX: ROP and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SWX: ROP’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma
CompanyDrug

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

Johnson & Johnson (J&J; NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication…

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

FDA Approves Roche's Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

FDA Approves Roche’s Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute

CompanyDrug

Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer

CompanyDeals

Roche Boosts China Investment with Additional RMB 250 Million

Show More